Details:

Alternative Title:
Hum Reprod
Publisher's site:
http://dx.doi.org/10.1093/humrep/der315
Personal Author:
Munsie, JeanPierre W.; Lin, Shao; Browne, Marilyn L.; Campbell, Kimberly A.; Caton, Alissa R.; ... More +
Munsie, JeanPierre W.; Lin, Shao; Browne, Marilyn L.; Campbell, Kimberly A.; Caton, Alissa R.; Bell, Erin M.; Rasmussen, Sonja A.; Romitti, Paul A.; Druschel, Charlotte M.; Less -
Description:
BACKGROUND Few epidemiological studies have explored the relationship between orofacial clefts and bronchodilators. We assessed whether mothers who used bronchodilators during early pregnancy were at an increased risk of delivering infants with orofacial clefts. METHODS We used National Birth Defects Prevention Study case–control data from mothers of 2711 infants with orofacial clefts and 6482 mothers of live born infants without birth defects, delivered during 1997 through 2005. Information on medication use from 3 months before pregnancy through delivery was collected using a standardized interview . Logistic regression was used to estimate adjusted odds ratios (aOR) and 95% confidence intervals (CIs) for maternal bronchodilator use during the periconceptional period (1 month before pregnancy through the third month of pregnancy) while controlling for other covariates. RESULTS We observed an association between maternal bronchodilator use during the periconceptional period and cleft lip only (CLO) (aOR = 1.77, 95% CI: 1.08–2.88). The risk of cleft palate only (CPO) (aOR = 1.53, 95% CI: 0.99–2.37) was elevated but was not statistically significant. No association was observed for maternal bronchodilator use and the risk of cleft lip with cleft palate (aOR = 0.78, 95% CI: 0.46–1.31). The most commonly used bronchodilator was albuterol (88.7%). Maternal albuterol use was associated with CLO (aOR = 1.79, 95% CI: 1.07–2.99) and CPO (aOR = 1.65, 95% CI: 1.06–2.58). CONCLUSIONS We observed a statistically significant association between maternal bronchodilator use during the periconceptional period and the risk of CLO after controlling for other risk factors. It is unclear whether the increased odds ratios observed in this study are due to the bronchodilators, the severity of asthma, or both, or to chance alone. Further studies to disentangle the role of asthma or asthma medications would help clarify these findings.
Subject:
[+]
Adult
Article
Asthma
Birth Defects
Bronchodilator Agents
Case-Control Studies
Cleft Lip
Cleft Palate
Congenital Abnormalities
Female
Humans
Infant, Newborn
Male
Maternal Exposure
Models, Statistical
Mothers
Odds Ratio
Orofacial Clefts
Pregnancy
Pregnancy Complications
Regression Analysis
Risk
Risk Factors
Bronchodilator Agents

Source:
Hum Reprod. 26(11):3147-3154.;
Pubmed ID:
21926056
Pubmed Central ID:
PMC6034617
Document Type:
Journal Article;
Funding:
U01 DD000487/DD/NCBDD CDC HHS/United States; U01 DD000492/DD/NCBDD CDC HHS/United States; U01/DD00048702/DD/NCBDD CDC HHS/United States;
U01 DD000487/DD/NCBDD CDC HHS/United States; U01 DD000492/DD/NCBDD CDC HHS/United States; U01/DD00048702/DD/NCBDD CDC HHS/United States; Less -
Collection(s):
CDC Public Access
Main Document Checksum:
[+]
urn:sha256:d856c4379e91246c3192f67cc4b7a493b2ab7ddb25da51f1c9903f3b5952100c
File Type:

Supporting Files

• nihms977663.nxml

  xml

More +